Your browser doesn't support javascript.
loading
Opioid receptor antagonism and neural response to monetary rewards: Pilot studies in light and heavy alcohol users.
Gowin, Joshua L; Sloan, Matthew E; Kirk-Provencher, Katelyn T; Rosenblatt, Sophie L; Penner, Anne E; Stangl, Bethany L; Byrd, Nia D; Swan, Julia E; Ramchandani, Vijay A.
Afiliação
  • Gowin JL; Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Sloan ME; Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.
  • Kirk-Provencher KT; Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada.
  • Rosenblatt SL; Division of Neurosciences and Clinical Translation, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Penner AE; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
  • Stangl BL; Department of Psychological Clinical Science, University of Toronto Scarborough, Toronto, ON, Canada.
  • Byrd ND; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Swan JE; Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Ramchandani VA; Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
J Psychopharmacol ; 37(9): 937-941, 2023 09.
Article em En | MEDLINE | ID: mdl-37530456
ABSTRACT
Alcohol use disorder (AUD) is a prevalent condition associated with high degree of comorbidity and mortality. Among the few approved pharmacotherapies for AUD, two involve opioid receptor antagonism. Naltrexone and nalmefene are thought to act via opioid receptor blockage to reduce neural response to alcohol and drug-associated cues and consumption, but there have been limited efforts to characterize these effects in humans. In these studies, we sought to test the magnitude of opioid antagonism effects on neural response to monetary rewards in two groups light drinkers (for the naltrexone study) and heavy drinkers (for the nalmefene study). We conducted double-blind, randomized, crossover pilot studies of reward activation in the brain following acute administration of opioid antagonist and placebo in 11 light and 9 heavy alcohol users. We used a monetary incentive delay task during functional MRI. We found a main effect of cue type on BOLD activation in the nucleus accumbens, demonstrating a neural reward response. The effect of opioid antagonism, relative to placebo, was small and nonsignificant for reward activation in the accumbens for both light and heavy alcohol users. Based on the results of two pilot studies, opioid antagonist medications do not appear to decrease neural activation to monetary rewards in the nucleus accumbens relative to placebo.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Alcoolismo / Antagonistas de Entorpecentes Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Alcoolismo / Antagonistas de Entorpecentes Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article